You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patiAlready a subscriber Login…
Calliditas Therapeutics has announced that a $5 million milestone payment from its partner Everest Medicines II Limited has been triggered as per the licensing agreement under which Everest is to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore. Already a subscriber Login You have read…
GE Healthcare Life Sciences opens the company's first cell and gene therapy laboratory in Asia, aiming to enable new developments and commercialization of precision medicine in Asia. According to the company, the center, aligned to GE Healthcare’s Fast Trak China offering, marks a milestoneAlready a subscriber Login You have read all your free articles,…
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with an irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACPAlready a subscriber Login You have read all your free…
